Business UpdateJun 4, 2026, 08:01 AM
Diginex Launches Risk-to-Remedy Supply Chain Due Diligence Solution
AI Summary
Diginex Limited announced the integration of Risk-to-Remedy as an end-to-end supply chain due diligence solution, marking the next phase of its supply chain offering. This solution, built on LUMEN and APPRISE and enhanced by The Remedy Project acquisition, aims to close the gap between declared and demonstrated compliance. The human rights and supply chain due diligence market is valued at $3.8 billion in 2025 and is projected to grow to $9.6 billion by 2034, driven by increasing regulatory demands and investor scrutiny. Diginex plans further enhancements to its offering to improve assessment management, evidence collection, and compliance monitoring.
Key Highlights
- Diginex launched Risk-to-Remedy, an end-to-end supply chain due diligence solution.
- The human rights and supply chain due diligence market is valued at approximately $3.8 billion in 2025.
- The market is projected to reach $9.6 billion by 2034, driven by tighter regulation and investor scrutiny.
- Risk-to-Remedy integrates worker-level evidence, prioritized remediation, and regulator-ready reporting.
- Upcoming enhancements will enable more efficient management of assessments, evidence, and non-compliance monitoring.
- The solution is built on LUMEN and APPRISE, strengthened by The Remedy Project acquisition.
Price Impact
More from DGNX